Results
|
|
1.
|
Neuropsychiatric safety with liraglutide 3.0mg for weight management: results from randomized controlled phase 2 and 3a trials. MedStar authors:
Year: 2017
Citation: - Diabetes, Obesity & Metabolism. 19(11):1529-1536, 2017 Nov.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Astrup A, Brett J, Cancino A, Kushner R, Lau DC, O'Neil PM, Satiety and Clinical Adiposity - Liraglutide Evidence in individuals with and without diabetes (SCALE) study groups, Wadden TA, Wilding JP
|
|
|
2.
|
Consistent findings in glycaemic control, body weight and hypoglycaemia with iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) versus insulin glargine across baseline HbA1c, BMI and diabetes duration categories in the LixiLan-L trial. MedStar authors:
Year: 2017
Citation: - Diabetes, Obesity & Metabolism. 19(10):1408-1415, 2017 Oct.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Bergenstal RM, Bonadonna RC, Kapitza C, LixiLan-L trial investigators, Niemoeller E, Puig-Domingo M, Souhami E, Stager W, Wysham C, Yu C
|
|
|
3.
|
Androgens, irregular menses, and risk of diabetes and coronary artery calcification in the Diabetes Prevention Program. MedStar authors:
Year: 2018
Citation: - Journal of Clinical Endocrinology & Metabolism. 103(2):486-496, 2018 02 01.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Carrion-Petersen M, Diabetes Prevention Program Outcomes Study Group, Edelstein SL, Ehrmann DA, Goldberg RB, Kim C, Younes N
|
|
|
4.
|
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. MedStar authors:
Year: 2018
Citation: - Diabetes Care. 41(2):258-266, 2018 02.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Ahmann AJ, Annett MP, Aroda VR, Capehorn M, Charpentier G, Dotta F, Henkel E, Holst AG, Lingvay I
|
|
|
5.
|
Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. [Review] MedStar authors:
Year: 2017
Citation: - Diabetologia. 60(9):1601-1611, 2017 Sep.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Crandall JP, Darwin C, Diabetes Prevention Program Research Group, Edelstein SL, Heckman-Stoddard BM, Jeffries SL, Kahn SE, Knowler WC, Molitch ME, Nathan DM, Perreault L, Pi-Sunyer X, Temprosa M
|
|
|
6.
|
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. MedStar authors:
Year: 2017
Citation: - The Lancet Diabetes & Endocrinology. 5(5):355-366, 2017 May
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Axelsen M, Bain SC, Cariou B, DeVries JH, Piletic M, Rose L, Rowe E
|
|
|
7.
|
Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS). MedStar authors:
Year: 2017
Citation: - Diabetic Medicine. 34(12):1747-1755, 2017 Dec.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Barrett-Connor E, Dabelea D, Dagogo-Jack S, Hamman RF, Kahn SE, Knowler WC, Mather KJ, Pan Q, Perreault L, The Diabetes Prevention Program Research Group
|
|
|
8.
|
|
|
|
9.
|
|
|
|
10.
|
|
